Trials / Terminated
TerminatedNCT00862836
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-centre, non-randomized open phase I/randomized phase II study will be conducted in 70 patients (10 in phase I, 60 in phase II) with platinum-refractory recurrent epithelial cancer of the ovary, fallopian tube or peritoneum. A total of approximately 5 national centers will participate in phase I of the study. If the starting criteria for phase II of the study are met at the end of phase I, a total of approximately 20 national centers will participate in phase II of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vandetanib | 100mg doses orally, once daily |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2009-03-17
- Last updated
- 2016-10-10
- Results posted
- 2012-10-11
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00862836. Inclusion in this directory is not an endorsement.